Table 1.
Baseline characteristics of patients with and without simvastatin treatment
| Statin (n = 2753) | Statin-free (n = 866) | p | |
|---|---|---|---|
| Age, y | 62.8 ± 6.7 | 62.9 ± 6.4 | 0.79 |
| Sex, n (%) | < 0.01 | ||
| Female | 843(30.6) | 482(55.7) | |
| Male | 1910(69.4) | 384(44.3) | |
| Race, n (%) | < 0.01 | ||
| White | 1789(65.0) | 466(53.8) | |
| Black | 438(15.9) | 246(28.4) | |
| Hispanic | 194(7.0) | 54(6.2) | |
| Other | 332(12.1) | 100(11.5) | |
| BMI, kg/m2 | 32.4 ± 5.4 | 32.2 ± 6.0 | 0.45 |
| Duration of diabetes, y | 9(5,15) | 9(5,15) | 0.84 |
| HbA1c, % | 8.1(7.5,8.8) | 8.1(7.6,9.0) | 0.01 |
| Fasting plasma glucose, mg/dL | 169(139,204) | 170(138,209) | 0.27 |
| Duration of hypertension, y | 7(3,15) | 7(2,16) | 0.22 |
| SBP(BL), mmHg | 134.0 ± 17.9 | 140.5 ± 16.8 | < 0.01 |
| DBP(BL), mmHg | 74.0 ± 10.9 | 77.4 ± 10.7 | < 0.01 |
| Duration of hyperlipidemia, y | 4(2,8) | 4(1,9) | 0.86 |
| Triglycerides, mg/dL | 160(113,227) | 140(94,219) | < 0.01 |
| Total cholesterol, mg/dL | 175.7 ± 37.9 | 197.6 ± 46.0 | < 0.01 |
| HDL-C, mg/dL | 38.2 ± 7.8 | 47.6 ± 15.6 | < 0.01 |
| LDL-C, mg/dL | 101.1 ± 30.9 | 114.4 ± 39.0 | < 0.01 |
| VLDL-C, mg/dL | 32(23,45) | 28(19,44) | < 0.01 |
| Retinopathy, n (%) | 279(11.7) | 84(11.2) | 0.79 |
| UACR, mg/g | 14(7,44) | 15(7,49) | 0.38 |
| Serum creatinine, mg/dL | 0.9(0.8,1.0) | 0.8(0.7,1.0) | < 0.01 |
| eGFR, ml/min/1.73 m2 | 89.6(75.4,104.7) | 90.4(77.8,107.5) | < 0.01 |
| intensive glycemic control, n (%) | 1383(50.2) | 414(47.8) | 0.23 |
| ACEi/ARB, y | 4(2,5) | 4(1,5) | 0.34 |
| SBP(EXIT), mmHg | 130.2 ± 17.7 | 130.3 ± 18.7 | 0.82 |
| DBP(EXIT), mmHg | 68.9 ± 10.6 | 69.5 ± 10.9 | 0.15 |
BMI Body Mass Index; HbA1c Glycosylated Hemoglobin, Type A1c; SBP(BL) Systolic Blood Pressure (Baseline); DBP(BL) Diastolic Blood Pressure (Baseline); HDL-C High-density lipoprotein cholesterol; LDL-C Low-density lipoprotein cholesterol; VLDL-C Very low-density lipoprotein cholesterol; UACR Urine Albumin-to-Creatinine Ratio; eGFR estimated glomerular filtration rate; ACEi Angiotensin-converting enzyme inhibitor; ARB angiotensin II receptor blocker